Zrinka Mršić-Krmpotić

Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial

Jacek Jassem, Tadeusz Pieńkowski, A Płużańska et al. · Journal of Clinical Oncology · 2001 · 308 citations

Medicine, Oncology, Pharmacology +17

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With <i>HER2-</i>Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

Vicente Valero, John Forbes, Mark D. Pegram et al. · Journal of Clinical Oncology · 2010 · 259 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

Christoph Zielinski, S. Beslija, Zrinka Mršić-Krmpotić et al. · Journal of Clinical Oncology · 2005 · 63 citations · Full text

Medicine, Oncology, Pharmacology +14

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Thomas Brodowicz, Tudor–Eliade Ciuleanu, Davorin Radosavljević et al. · Annals of Oncology · 2013 · 57 citations

Medicine, Oncology, Pharmacotherapy +13

Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer

A. Płuż zańska, Jacek Jassem, S. Jelić et al. · European Journal of Cancer · 1999 · 12 citations

Medicine, Oncology, Pharmacology +15